Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil for Switch-Maintenance Prophylaxis of GVHD in Allogeneic HCT
NCT07006506Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in graft-versus-host disease (GVHD), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2025; status: recruiting.
02
Drugs
belumosudil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07006506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006506.